PCSK9 and familial hypercholesterolemia: Taken together, cell and animal models and patient cohorts relevant for chronic liver diseases and treated with pharmacological PCSK9 inhibitors have revealed multiple layers of additional PCSK9 functions that extend well beyond its therapeutic aspect in overcoming hypercholesterolemia.